Dianthus Therapeutics, Inc. - Common Stock (NQ:DNTH)

52.49 -0.27 (-0.51%)

Streaming Delayed Price Updated: 12:29 PM EST, Jan 23, 2026 Add to My Watchlist

Price and Volume

Volume	224,205
Open	52.41
Bid (Size)	52.34 (200)
Ask (Size)	52.49 (100)
Prev. Close	52.76
Today's Range	51.47 - 53.79
52wk Range	13.37 - 54.00
Shares Outstanding	60,648,883
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Dianthus CFO Sells 20,000 Shares for $903,600 After Massive Year-End Run ↗

January 07, 2026

This biotech developing therapies for rare autoimmune diseases reported notable insider selling in its most recent SEC disclosure.

Via The Motley Fool

Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare Conference

January 05, 2026

From Dianthus Therapeutics, Inc.

Via GlobeNewswire

Performance

YTD	+32.3%	+32.3%
1 Month	+23.2%	+23.2%
3 Month	+57.8%	+57.8%
6 Month	+140.9%	+140.9%
1 Year	+131.6%	+131.6%

More News

Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)

December 23, 2025

From Dianthus Therapeutics, Inc.

Via GlobeNewswire

Dianthus Therapeutics To Participate in the 8th Annual Evercore Healthcare Conference

November 24, 2025

From Dianthus Therapeutics, Inc.

Via GlobeNewswire

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results

November 05, 2025

From Dianthus Therapeutics, Inc.

Via GlobeNewswire

Dianthus Therapeutics to Participate in Four Investor Conferences During November

November 04, 2025

From Dianthus Therapeutics, Inc.

Via GlobeNewswire

Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting

October 29, 2025

From Dianthus Therapeutics, Inc.

Via GlobeNewswire

Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases

October 16, 2025

From Dianthus Therapeutics, Inc.

Via GlobeNewswire

General Motors To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Friday ↗

September 12, 2025

Via Benzinga

Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting

October 02, 2025

From Dianthus Therapeutics, Inc.

Via GlobeNewswire

3 Biotech Stocks Showing Strength With Big Spikes In Momentum Scores ↗

September 12, 2025

Via Benzinga

Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

September 11, 2025

From Dianthus Therapeutics, Inc.

Via GlobeNewswire

Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering

September 09, 2025

From Dianthus Therapeutics, Inc.

Via GlobeNewswire

Analyst Expectations For Dianthus Therapeutics's Future ↗

September 09, 2025

Via Benzinga

Dianthus Therapeutics, Inc. Announces Proposed $150 Million Underwritten Public Offering

September 08, 2025

From Dianthus Therapeutics, Inc.

Via GlobeNewswire

Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again ↗

September 08, 2025

Via Investor's Business Daily

Dianthus Scores Early Success, Analyst Boosts Confidence In Broader Drug Pipeline ↗

September 08, 2025

Via Benzinga

Top movers in Monday's pre-market session ↗

September 08, 2025

Via Chartmill

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

September 08, 2025

Via Benzinga

Dianthus Therapeutics Announces Positive Data for Claseprubart (DNTH103) from the Phase 2 MaGic Trial in Generalized Myasthenia Gravis, Supporting Its Potential Best-In-Class Profile

September 08, 2025

From Dianthus Therapeutics, Inc.

Via GlobeNewswire

Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis

September 07, 2025

From Dianthus Therapeutics, Inc.

Via GlobeNewswire

The Oncology Institute Announces Changes to Board of Directors

August 13, 2025

From Toi Management, LLC

Via GlobeNewswire

Dianthus Therapeutics Inc (NASDAQ:DNTH) Q2 2025 Earnings: Revenue Misses, EPS Meets Estimates ↗

August 07, 2025

Via Chartmill

Dianthus (DNTH) Q2 Loss Widens 80% ↗

August 07, 2025

Via The Motley Fool

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results

August 07, 2025

From Dianthus Therapeutics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Dianthus Therapeutics, Inc. - Common Stock publicly traded?

Yes, Dianthus Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Dianthus Therapeutics, Inc. - Common Stock trade on?

Dianthus Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Dianthus Therapeutics, Inc. - Common Stock?

The ticker symbol for Dianthus Therapeutics, Inc. - Common Stock is DNTH on the Nasdaq Stock Market

What is the current price of Dianthus Therapeutics, Inc. - Common Stock?

The current price of Dianthus Therapeutics, Inc. - Common Stock is 52.49

When was Dianthus Therapeutics, Inc. - Common Stock last traded?

The last trade of Dianthus Therapeutics, Inc. - Common Stock was at 01/23/26 12:29 PM ET

What is the market capitalization of Dianthus Therapeutics, Inc. - Common Stock?

The market capitalization of Dianthus Therapeutics, Inc. - Common Stock is 3.18B

How many shares of Dianthus Therapeutics, Inc. - Common Stock are outstanding?

Dianthus Therapeutics, Inc. - Common Stock has 3B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.